Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) has provided an update.
Beijing Biostar Pharmaceuticals Co., Ltd. announced a change in its auditor due to a shift from HKFRS Accounting Standards to China Accounting Standards for Business Enterprises (CASBE) for its financial statements. This decision led to the appointment of WUYIGE Certified Public Accountants LLP, which has more expertise in CASBE, replacing Daxin Global (HK) CPA Limited. The change reflects the company’s strategic move to align its financial reporting with local standards, potentially impacting its audit processes and stakeholder relations.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development and production of biological and pharmaceutical products.
Average Trading Volume: 667,360
Technical Sentiment Signal: Hold
For a thorough assessment of 2563 stock, go to TipRanks’ Stock Analysis page.